Efficacy and safety of umbilical cord mesenchymal stem cell transplantation in patients with autoim-mune liver diseases

吕胜祥,乔晓,梁凤,王昌成,别小芹,甘建和

DOI: https://doi.org/10.3969/j.issn.1672-5069.2015.05.013

2015-01-01

Abstract:Objective To investigate the safety and efficacy of umbilical cord mesenchymal stem cell (UC-MSCs) transplantation in patients with autoimmune liver diseases (AILD). Methods The 8×107 UC-MSCs were transfused intravenously in six patients with AILD through the peripheral vein. Serum fetoprotein ,interferon-γand interleukin (IL)-4 levels were detected by ELISA. Results After the UC-MSCs therapy,the six patients achieved clinical remission with elevated albumin (ALB) [(38.85±6.98) g/L vs. (33.51±5.32) g/L,P<0.05],and de-creased alanine aminotransferase [ALT,(69.95±47.96) U/L vs. (39.65±18.87) U/L)] and AST [(65.71±43.64) U/L vs.(35.52±17.24) U/L,P<0.05 for both];However,no significant changes in bilirubin,alkaline phosphatase and glu-tamy transpeptidase were observed after the treatment (P>0.05);There were no side effects after the treatment;The baseline serum IFN-γ and IL-4 before the treatment were (139.30~219.34) pg/ml and (29.31~55.23) pg/ml, respectively,and 24 months later,serum IFN-γ levels declined to [(116.82~167.65) pg/ml,P=0.0368] and serum IL-4 levels increased to [(43.89~69.99) pg/ml,P=0.0418]. Conclusion UC-MSCs therapy can effectively attenu-ate the clinical symptoms and improve the liver function in AILD patients without any severe adverse effects ,and the probable mechanism may lie on the correction of immune dysfunction by UC-MSCs.